A method of treating a sacroiliac joint and/or a region proximate the sacroiliac joint includes distracting and/or stabilizing a recess between a sacral wall of a sacrum and an ilial wall of an ilium, cutting a surface of the ilial wall using a cutting device, and positioning an implant having a first planar wall and a second planar wall opposite the first planar wall into the recess, such that the first planar wall of the implant is in contact with an uncut surface of the sacral wall, and the second planar wall is in contact with the cut surface of the ilial wall. The implant can be formed as a wedge-shape, a double-wedge shape, or a cuboid shape.
A battery management system comprises: a circuit path electrically coupling a battery and a load; a backup storage device; a first switch connecting the battery and the backup storage device; a second switch connecting the backup storage device and the load; a sensor for measuring a temperature of the battery; and a controller in electrical communication with the first switch, the second switch, and the sensor. The controller executes a program to: (i) activate the first switch to connect the battery and the backup storage device for charging the backup storage device for a charging period of time with power provided by the battery based on the temperature of the battery meeting a threshold, and (ii) activate the second switch to connect the backup storage device and the load for providing power to the load from the backup storage device after the charging period of time has expired.
H01M 10/633 - Control systems - characterised by algorithms, flow charts, software details or the like
H01M 10/635 - Control systems based on ambient temperature
H01M 10/65 - Means for temperature control structurally associated with the cells
H01M 10/651 - Means for temperature control structurally associated with the cells characterised by parameters specified by a numeric value or mathematical formula, e.g. ratios, sizes or concentrations
3.
SYSTEMS AND METHODS FOR TREATING A WASTEWATER STREAM
Provided herein are systems and methods for treating a wastewater stream. In one embodiment, a wastewater stream is treated using a settling tank, a membrane feed tank, and at least one filtration unit.
UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF NASA (USA)
Inventor
Yeh, Daniel H.
Pickett, Melanie T.
Roberson, Luke
Calabria, Jorge L.
Bullard, Talon
Abstract
A closed-loop, bioregenerative water purification system including a gravity-independent anaerobic membrane bioreactor capable of operating in the presence and absence of gravity, the bioreactor including an anaerobic bioreactor, a first membrane filtration unit, and a second membrane filtration unit, wherein the anaerobic bioreactor is configured to receive organic waste and hygiene water as inputs and break them down into constituent components using anaerobic microbes, wherein the first membrane filtration unit is configured to receive effluent output from the anaerobic bioreactor, return concentrate to the anaerobic bioreactor, and output permeate to the second membrane filtration unit, and wherein the second membrane filtration unit is configured to receive the permeate output from the first membrane filtration unit, separate biogas from the permeate, and output nutrient-rich water.
B01D 29/50 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups ; Filtering elements therefor with multiple filtering elements, characterised by their mutual disposition
B01D 43/00 - Separating particles from liquids, or liquids from solids, otherwise than by sedimentation or filtration
The present invention provides pharmaceutical compositions and methods for use and manufacture thereof. The pharmaceutical compositions comprise a therapeutically effective amount of a cannabinoid or a pharmaceutically acceptable salt or solvate thereof and an amphiphilic copolymer comprising at least one hydrophilic component and at least one hydrophobic component. The cannabinoid is encapsulated in the amphiphilic copolymer, and the composition is suitable for intranasal or inhalation delivery.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Peterson, Matthew J.
Cowan, Linda J.
Hall, Kimberly S.
Goldgof, Dmitry
Sarkar, Sudeep
Pai, Chih-Yun
Morera, Hunter
Sun, Yu
Abstract
Methods and systems for imaging and analysis are described. Accurate pressure ulcer measurement is critical in assessing the effectiveness of treatment. However, the traditional measuring process is subjective. Each health care provider may measure the same wound differently, especially related to the depth of the wound. Even the same health care provider may obtain inconsistent measurements when measuring the same wound at different times. Also, the measuring process requires frequent contact with the wound, which increases risk of contamination or infection and can be uncomfortable for the patient. The present application describes a new automatic pressure ulcer monitoring system (PrUMS), which uses a tablet connected to a 3D scanner, to provide an objective, consistent, non-contact measurement method. The present disclosure combines color segmentation on 2D images and 3D surface gradients to automatically segment the wound region for advanced wound measurements.
One aspect described herein relates to a recombinant adeno-associated virus (rAAV) vector and a method for use thereof for treating Angelman Syndrome. Another aspect described herein is a UBE3A rAAV vector and method for use thereof for treating a UBE3A deficiency, e.g. Angelman syndrome, in humans.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A system and method for assessing a supply chain for a perishable product. In various embodiments, the present invention provides a quality code for a perishable product which encodes a plurality of the most important performance metrics of the cold chain for the perishable product, including food quality oriented measures such as cut-to-cool time, transportation quality and accumulated shelf-life loss, and food safety oriented measures such as most probable number range for microorganism growth into a compact, modular and simple to read format.
A composition, workout/exercise supplement, treatment method for conditions associated with vasoconstriction, and method of extracting galloylated procyanidins. The composition includes galloylated procyanidins having a preponderance of (-)-epicatechins. The treatment methods include administering a therapeutically effective amount of galloylated procyanidins having a preponderance of (-)-epicatechins. The extraction methods include isolating galloylated procyanidins having a preponderance of (-)-epicatechins from a sample that contains polyphenols, catechins, epicatechins, and galloylated epicatechins.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 9/00 - Drugs for disorders of the cardiovascular system
Disclosed herein are exogenous antigen sensitized immature dendritic cells. The dendritic cell may also be dead. The exogenous antigen sensitized immature dendritic cells may be used to elicit an increased immune response. Further provided are vaccines comprising the exogenous antigen sensitized immature dendritic cells, methods, of inducing an immune response in a patient, and methods of treating a disease.
The present invention provides a method and system for producing liquid fuel from landfill gas, the method comprising: (i) providing O2, steam and landfill gas comprising 30 to 70 %mol methane and 35 to 55 %mol CO2 to a single tri-reformer reactor comprising a first catalyst; (ii) supplying energy to said single tri-reformer reactor; (iii) performing a tri-reforming process on said landfill gas, wherein said tri- reforming process comprises carbon dioxide reforming, steam reforming, water-gas shifting, and methane oxidation, to produce synthesis gas having a H2:CO ratio of approximately 2:1; (iv) providing the synthesis gas to a Fischer-Tropsch synthesis (FTS) reformer comprising a second catalyst; (v) converting said synthesis gas into liquid fuel, fuel gas and steam within the FTS reformer; and (vi) combusting at least some of said fuel gas to provide said energy to said tri-reformer reactor, whereby said method for producing liquid fuel is at least partially self-sufficient in terms of energy for said tri-reforming process.
C10G 2/00 - Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon
C01B 3/38 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts
12.
MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME
A novel vector, composition and method of treating a neurological disorder characterized by deficient UBE3A is presented. The UBE3A gene, which encodes for E6-AP, a ubiquitin ligase, was found to be responsible for Angelman syndrome (AS). A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. A UBE3A protein construct was generated with additional sequences that allow the secretion from cells and uptake by neighboring neuronal cells. This UBE3A vector may be used in gene therapy to confer a functional E6-AP protein into the neurons and rescue disease pathology.
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Mohapatra, Shyam S.
Mohapatra, Subhra
Abstract
The present invention pertains to a strategy of selectively targeting oncolytic virotherapy, using either naturally occurring or genetically modified viruses by packaging them in mesenchymal stem cells (MSCs). The present invention concerns MSCs, compositions comprising the MSCs, and methods of using the MSCs for treatment of cancer and for lysing or inducing apoptosis of cancer cells in vitro or in vivo.
Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia. Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reelin, or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.
A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
15.
METHODS OF SCREENING DRUGS FOR CANCER TREATMENT USING CELLS GROWN ON A FIBER-INSPIRED SMART SCAFFOLD
Described are methods of screening drugs for cancer treatment using a fiber-inspired smart scaffold cell culture system. The system recapitulates the actual in vivo tumor microenvironment, thereby ensuring efficacy in clinical trials by identifying drugs that will be effective in treating cancer. The drugs identified by the system may then be used to treat cancers, including breast cancer and colorectal adenocarcinoma. In addition, this screening system provides a platform for methods relating to the personalized treatment of cancer.
Angelman Syndrome (AS) is a genetic disorder occurring in one in every 15,000 births. It is characterized by severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A and encodes for E6-AP, an ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes are associated with AS. We have generated a Ube3a protein with additional sequences that should allow the secretion from cells and uptake by neighboring neuronal cells. This would confer a functional E6-AP protein into the neurons and rescue disease pathology.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
17.
RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
WAKE FOREST UNIVERSITY (USA)
MODULATION THERAPEUTICS, INC. (USA)
Inventor
Morse, David
Gillies, Robert
Mclaughlin, Mark
Wadas, Thaddeus
Kil, Hyun Joo
Tafreshi, Narges
Abstract
The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
Described herein are compositions and methods of forming multi-cellular tumoroids. Also described herein are methods of using the multi-cellular tumoroids.
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Sarnaik, Amod A.
Pilon-Thomas, Shari
Mclaughlin, Mark
Liu, Hao
Abstract
Disclosed are compositions and methods for ex vivo expansion of tumorinfiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumorinfiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.
A61P 35/04 - Antineoplastic agents specific for metastasis
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
20.
THREE DIMENSIONAL FIBROUS SCAFFOLDS FOR CELL CULTURE
Provided herein is a three-dimensional scaffold composition comprising randomly oriented fibers, wherein the fibers comprise a polyethylene glycol-polylactic acid block copolymer (PEG-PLA) and a poly(lactic-co-glycolic acid) (PLGA). Also provided are methods for using the three-dimensional scaffolds described herein.
Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, acheiving blood ketone levels of (2 - 7mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A method of treating cancer using ketogenic diet, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient.
Disclosed herein are methods for the treatment of traumatic brain injury by transplantation of cells descended from marrow adherent stem cells that express an exogenous Notch intracellular domain. The transplanted cells form a pathway along which endogenous neurogenic cells proliferate and migrate from the subventricular zone to the site of injury.
The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotevtion against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultural cortex neurons exposed to hyperbaric oxygen and A.beta.-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol aceoacetate monoester, R,S-L3-butanediol acetoacetate diester, or a combination of the two.
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Hazlehurst, Lori
Mclaughlin, Mark
Jain, Priyesh
Dalton, William S.
Abstract
Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interacts with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etopside.
This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Described are mathematical models and method, e.g., computer-implemented methods, for predicting tumor sensitivity to radiation therapy, which can be used, e.g., for selecting a treatment for a subject who has a tumor.
The subject invention concerns non-degradable three dimensional porous collagen scaffolds and coatings. These scaffolds can be prepared around sensors for implantation into a body. A specific embodiment of the invention concerns implantable glucose sensors. Sensors comprising a collagen scaffold of the invention have improved biocompatibility by minimizing tissue reactions while stimulating angiogenesis. The subject invention also concerns methods for preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
YALE UNIVERSITY (USA)
UNIVERSITY OF SOUTH FLORIDA (USA)
Inventor
Turkson, James
Hamilton, Andrew D.
Jove, Richard
Sebti, Said M.
Abstract
A small-molecule Stat3 dimerization inhibitor, S3I-M2001. is described and the dynamics of intracellular processing of activated Stat3 within the context of the biochemical and biological effects of the Stat3 chemical probe inhibitor are elucidated. S3I-M2001 is a newly-identified oxazole-based peptidomimetic of the Stat3 Src Homology (SH) 2 domain-binding phosphotyrosine peptide that selectively disrupts active Stat3:Stat3 dimers. Stat3-dependent malignant transformation, survival, and migration and invasion of mouse and human cancer cells harboring persistently-activated Stat3 were inhibited by S3I-M2001. S3I-M2001 inhibited Stat3-dependent transcriptional regulation of tumor survival genes, such as Bcl-xL. The disclosed compound is useful as a new potential treatment for certain cancers.
The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.
The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
C07H 19/23 - Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups
32.
USES OF IL-2 AS A THERAPEUTIC MEDICAMENT IN COMBINATION WITH ELECTROPORATION FOR THE TREATMENT OF MALIGNANCIES
In accordance, with the present invention is provided a use of a plasmid coding for Inte1eukin-12 (IL-12) as a therapeutic medicament providing for the regression of an established cancerous tumor in a subject. The plasmid is used with at least one electroporative electric pulse of at least 700V/cm and of less than 1 millisecond duration configured for administration to the established cancerous tumor by an electroporation applicator to regress the established cancerous tumor.
patents
